Clinical trials: Epithelial Neoplasms, Malignant
Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well selumetinib works in treating patients with biliary cancer that cannot be removed by surgery.
- Conditions
- Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer, Unresectable Extrahepatic Bile Duct Cancer
- Trial name
- NCT00553332
- Testing
- selumetinib, laboratory biomarker analysis
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms, Metastases, Neoplasm
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
This is a phase II, multicenter, target enrollment of 250 evaluable patients, open-label study of cetuximab in patients with refractory, metastatic colorectal carcinoma.
- Trial name
- NCT00044863
- Testing
- Erbitux (Cetuximab)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer and Other Solid Tumors
APG-1252 in Patients With SCLC or Advanced Solid Tumors
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w.
- Trial name
- NCT03387332
- Testing
- APG-1252
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Ascentage Pharma Group Inc.
Bladder Cancer, Urothelial Carcinoma
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
This study aims to demonstrate that home instillation of UGN-102 is a feasible alternative to instillation in a clinical setting, which might mitigate patient challenges (logistical, expense, and comfort) when receiving treatment…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- NCT05136898
- Testing
- UGN-102
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- UroGen Pharma Ltd.
Hepatocellular Carcinoma
A Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary Single Photon Emission Tomography (SPECT)
Radiation-induced liver disease (RILD) is a syndrome characterized by the development of anicteric ascites approximately 2 weeks to 4 months after hepatic irradiation.
- Trial name
- NCT01519232
- Testing
- Liver Irradiation
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan Rogel Cancer Center
Small Cell Lung Cancer
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung…
- Trial name
- SKYSCRAPER-02 (NCT04256421)
- Testing
- Tiragolumab, Atezolizumab, Carboplatin
- Where
- 121 sites in United States, Australia and 21 more
- Volunteers
- 490 people
- Sponsor
- Hoffmann-La Roche
Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
The objective of this pivotal study is to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in patients with Barcelona Clinic Liver Cancer…
- Conditions
- Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- DOORwaY90 (NCT04736121)
- Testing
- Resin microspheres containing yttrium-90 (Y-90)
- Where
- 22 sites in United States
- Volunteers
- 100 people
- Sponsor
- Sirtex Medical
Colorectal Cancer, Non-Small Cell Lung Cancer
A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable CRC or locally advanced or metastatic NSCLC (excluding predominant squamous histology) who are receiving Avastin in…
- Trial name
- ARIES (NCT00388206)
- Volunteers
- 3,998 people
- Sponsor
- Genentech, Inc.
Pancreatic Cancer, Adenocarcinoma
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
The purpose of this phase I study to determine the optimal dose for the combination of IPI-926 plus FOLFIRINOX (5-fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) chemotherapy in patients with pancreatic cancer.
- Conditions
- Pancreatic Cancer, Adenocarcinoma, Pancreatic Neoplasms
- Trial name
- NCT01383538
- Testing
- FOLFIRINOX, IPI-926
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Andrew Ko
Liver Malignant Tumors, Cholangiocarcinoma Metastatic
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
Over the past three decades, the treatment of both primary and secondary liver malignancies has been improved by the development and optimization of multiple minimally invasive thermal ablative therapies.
- Conditions
- Liver Malignant Tumors, Cholangiocarcinoma Metastatic, Pancreatic Cancer, Melanoma
- Trial name
- NCT05053555
- Testing
- high dose rate brachytherapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
This phase Ib/II trial studies the side effects and best dose of aurora A kinase inhibitor LY3295668 when given together with osimertinib in patients with EGFR-mutant non-squamous non-small cell lung cancer that has spread to…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT05017025
- Testing
- Aurora A Kinase Inhibitor LY3295668, Osimertinib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC)
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors.
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer
- Trial name
- NCT07557225
- Testing
- 18F-T2 PET/CT
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Cancer of Head and Neck
Discontinuation of Tobacco Dependence in Smoking Patients With Squamous Cell Carcinoma of the Head-neck District: Multicenter Prospective Observational Study
The primary objective of our study is to evaluate the effectiveness of a standardized clinical practice counseling strategy for promoting post-diagnosis smoking cessation among patients with SCCHN.
- Trial name
- STOP-HNC (NCT06995417)
- Testing
- Smoking counseling
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Glioblastoma Multiforme
Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme
The purpose of this study is to determine the efficacy by the determination of the Time To Progression (TTP) in patients with resectable GBM or non surgical GBM with a size less than 5 cm treated with the combination of ZARNESTRA…
- Trial name
- NCT00209989
- Testing
- Zarnestra, standard Radiation therapy
- Where
- 2 sites in France
- Volunteers
- 27 people
- Sponsor
- Institut Claudius Regaud
Lung Carcinoma
Three-Dimensional Fluoroscopic Guidance During Transbronchial Cryobiopsy
This study assesses the effectiveness of transbronchial cryobiopsy guided by 3-dimensional fluoroscopy. Transbronchial cryobiopsy is a procedure to collect lung tissue.
- Trial name
- NCT05059691
- Testing
- Electronic Health Record Review, Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003691
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- 73 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Gynecologic Oncology Group
Glioma
A Study in Subjects With Recurrent Malignant Glioma
An open-label phase 2, multicenter study in participants with recurrent malignant glioma.
- Trial name
- NCT01137604
- Testing
- Lenvatinib, Bevacizumab
- Where
- 5 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Eisai Inc.
Carcinoma, Non-Small-Cell Lung (NSCLC)
Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer
This study will evaluate whether AG-013736 when combined with cisplatin and gemcitabine shows activity and is safe in patients with squamous type of non-small cell lung cancer
- Trial name
- NCT00735904
- Testing
- AG-013736, gemcitabine, cisplatin
- Where
- 10 sites in Poland, Romania and 2 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma
TACE as an Adjuvant Therapy After Hepatectomy for HCC
Investigators hypothesise that the use of transarterial chemoembolisation (TACE) after liver resection in patients with hepatocellular carcinoma can eradicate residual cancer cells in the liver and thus improve survival of…
- Trial name
- NCT01966133
- Testing
- Ethiodized Oil + Doxorubicin
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Jia Fan
Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
Expanded Access to ABT-414
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABT-414 prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Trial name
- NCT03123952
- Testing
- ABT-414
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.